{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-183563","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.622553+00:00","generated_at":"2026-05-15T02:52:39.233907+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Wave Q1 revenue $38.2M; net loss narrows to $26.1M; WVE-007 Phase 2a begins Q2 2026","bullets":["Revenue $38.2M (up from $9.2M); net loss $26.1M (vs $46.9M).","Cash $544.6M; runway into Q3 2028, excluding GSK milestones.","FDA accepted Phase 2a multidose portion of WVE-007 (obesity); trial to start Q2 2026.","Phase 1 six-month data: total fat -5.3%, visceral fat -14.3% (p<0.05), muscle +2.4%.","WVE-006 AATD data at ATS May 18 & EASL May 29; accelerated approval feedback mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-183563","json":"https://secwatch.observer/filing/0001193125-26-183563.json","markdown":"https://secwatch.observer/filing/0001193125-26-183563.md","text":"https://secwatch.observer/filing/0001193125-26-183563.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526183563/0001193125-26-183563-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526183563/d135689d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:52:39.233907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"feba5bae6690900e05fcbc16447085586890aa2d","claim":"Wave Life Sciences Ltd. reported financial results for quarter ended March 31, 2026.","evidence_excerpt":"On April 28, 2026, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526183563/0001193125-26-183563-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}